{
  "nctrialId": "HC-1427",
  "title": "A Randomized Open-Label, Active-Controlled  Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Non-Small Cell Lung Cancer",
  "officialTitle": "A Randomized Open-Label, Active-Controlled  Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Non-Small Cell Lung Cancer",
  "sponsor": "Alberta Health Services",
  "indication": "Non-Small Cell Lung Cancer",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1427.json",
  "fileSize": 116555,
  "date": "2023-10-20",
  "completionDate": "2026-04-15",
  "drugName": "PSO-602 (phosphodiesterase-4 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a randomized open-label, active-controlled  study designed to evaluate the efficacy and safety of PSO-602 (phosphodiesterase-4 inhibitor) in patients with Non-Small Cell Lung Cancer. The study will enroll approximately 258 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 19-64 years\n- Confirmed diagnosis of Non-Small Cell Lung Cancer\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n- Measurable disease per RECIST v1.1\n- Prior treatment with standard therapy\n- Life expectancy \u22653 months\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment\n- Brain metastases unless treated and stable\n- Prior treatment with similar mechanism of action\n- Other active malignancy requiring treatment",
  "csr_id": "HC-1427"
}